Kaitlin Blackstone Casaletto1, Henrik Zetterberg2,3,4,5, Kaj Blennow2,3,4, Ann Brinkmalm2,3,4, William Honer6, Julie A Schneider7, David A Bennett7, Nina Djukic8, Michelle You8, Sophia Weiner-Light8, Corrina Fonseca8, Bruce L Miller8, Joel Kramer8. 1. Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA kaitlin.casaletto@ucsf.edu. 2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 3. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 4. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. 5. UK Dementia Research Institute at UCL, London, UK. 6. Department of Psychiatry, University of British Columbia, Vancouver, BC. 7. Department of Neurological Sciences, Rush Medical College, Chicago, IL, USA. 8. Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Abstract
OBJECTIVE: To test the hypothesis that fundamental relationships along the amyloid, tau, and neurodegeneration (A/T/N) cascade depend on synaptic integrity in older adults in-vivo and postmortem. METHODS: Two independent observational, cross-sectional cohorts: 1) in-vivo community-dwelling, clinically normal adults from the UCSF Memory and Aging Center completed lumbar puncture and MRI (exclusion criteria, CDR>0), and 2) postmortem decedents from the Rush Memory and Aging Project (exclusion criteria, inability to sign informed consent). In-vivo measures included cerebrospinal fluid (CSF) synaptic proteins (synaptotagmin-1, SNAP-25, neurogranin, and GAP-43), Aβ42/40, ptau181, and MRI gray matter volume (GMV). Postmortem measures captured brain tissue levels of presynaptic proteins (complexin-I, complexin-II, VAMP, and SNARE complex), and neuritic plaque and neurofibrillary tangle (NFT) counts. Regression models tested statistical moderation of synaptic protein levels along the A/T/N cascade (synaptic proteins*amyloid on tau, and synaptic proteins*tau on GMV). RESULTS: 68 in-vivo older adults (age=71y, 43%F) and 633 decedents (age=90y, 68%F, 34% clinically normal) were included. Each in-vivo CSF synaptic protein moderated the relationship between Aβ42/40 and ptau181 (-0.23<𝛽s<-0.12, ps<0.05) and the relationship between ptau and GMV (-0.49<𝛽s<-0.32, ps<0.05). Individuals with more abnormal CSF synaptic protein demonstrated expected relationships between Aβ-ptau and ptau-brain volume, effects that were absent or reversed in those with more normal CSF synaptic protein. Postmortem analyses recapitulated CSF models. More normal brain tissue levels of complexin-I, VAMP, and SNARE moderated the adverse relationship between neuritic plaque and NFT counts (-0.10<𝛽s<-0.08, ps<0.05). CONCLUSIONS: Pathogenic relationships of Aβ and tau may depend on synaptic state. Synaptic markers may help identify risk and/or resilience to AD proteinopathy.
OBJECTIVE: To test the hypothesis that fundamental relationships along the amyloid, tau, and neurodegeneration (A/T/N) cascade depend on synaptic integrity in older adults in-vivo and postmortem. METHODS: Two independent observational, cross-sectional cohorts: 1) in-vivo community-dwelling, clinically normal adults from the UCSF Memory and Aging Center completed lumbar puncture and MRI (exclusion criteria, CDR>0), and 2) postmortem decedents from the Rush Memory and Aging Project (exclusion criteria, inability to sign informed consent). In-vivo measures included cerebrospinal fluid (CSF) synaptic proteins (synaptotagmin-1, SNAP-25, neurogranin, and GAP-43), Aβ42/40, ptau181, and MRI gray matter volume (GMV). Postmortem measures captured brain tissue levels of presynaptic proteins (complexin-I, complexin-II, VAMP, and SNARE complex), and neuritic plaque and neurofibrillary tangle (NFT) counts. Regression models tested statistical moderation of synaptic protein levels along the A/T/N cascade (synaptic proteins*amyloid on tau, and synaptic proteins*tau on GMV). RESULTS: 68 in-vivo older adults (age=71y, 43%F) and 633 decedents (age=90y, 68%F, 34% clinically normal) were included. Each in-vivo CSF synaptic protein moderated the relationship between Aβ42/40 and ptau181 (-0.23<𝛽s<-0.12, ps<0.05) and the relationship between ptau and GMV (-0.49<𝛽s<-0.32, ps<0.05). Individuals with more abnormal CSF synaptic protein demonstrated expected relationships between Aβ-ptau and ptau-brain volume, effects that were absent or reversed in those with more normal CSF synaptic protein. Postmortem analyses recapitulated CSF models. More normal brain tissue levels of complexin-I, VAMP, and SNARE moderated the adverse relationship between neuritic plaque and NFT counts (-0.10<𝛽s<-0.08, ps<0.05). CONCLUSIONS: Pathogenic relationships of Aβ and tau may depend on synaptic state. Synaptic markers may help identify risk and/or resilience to AD proteinopathy.
Authors: Benjamin D Boros; Kelsey M Greathouse; Erik G Gentry; Kendall A Curtis; Elizabeth L Birchall; Marla Gearing; Jeremy H Herskowitz Journal: Ann Neurol Date: 2017-10-22 Impact factor: 10.422
Authors: L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue Journal: J Neurosci Date: 2000-06-01 Impact factor: 6.167
Authors: E Masliah; M Mallory; L Hansen; M Alford; T Albright; R DeTeresa; R Terry; J Baudier; T Saitoh Journal: Neuron Date: 1991-05 Impact factor: 17.173
Authors: Tara E Tracy; Peter Dongmin Sohn; S Sakura Minami; Chao Wang; Sang-Won Min; Yaqiao Li; Yungui Zhou; David Le; Iris Lo; Ravikumar Ponnusamy; Xin Cong; Birgit Schilling; Lisa M Ellerby; Richard L Huganir; Li Gan Journal: Neuron Date: 2016-03-31 Impact factor: 17.173
Authors: Charles C White; Hyun-Sik Yang; Lei Yu; Lori B Chibnik; Robert J Dawe; Jingyun Yang; Hans-Ulrich Klein; Daniel Felsky; Alfredo Ramos-Miguel; Konstantinos Arfanakis; William G Honer; Reisa A Sperling; Julie A Schneider; David A Bennett; Philip L De Jager Journal: PLoS Med Date: 2017-04-25 Impact factor: 11.069
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Daniel Alcolea; Jordi Pegueroles; Laia Muñoz; Valle Camacho; Diego López-Mora; Alejandro Fernández-León; Nathalie Le Bastard; Els Huyck; Alicia Nadal; Verónica Olmedo; Frederic Sampedro; Victor Montal; Eduard Vilaplana; Jordi Clarimón; Rafael Blesa; Juan Fortea; Alberto Lleó Journal: Ann Clin Transl Neurol Date: 2019-08-28 Impact factor: 4.511
Authors: Negin Holland; Maura Malpetti; Timothy Rittman; Elijah E Mak; Luca Passamonti; Sanne S Kaalund; Frank H Hezemans; P Simon Jones; George Savulich; Young T Hong; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe Journal: Brain Date: 2022-03-29 Impact factor: 15.255